Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study

REFERENCES

• Antiretroviral Therapy Cohort Collaboration. Life expec-tancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–299.
   PubMed Web of Science ®Google Scholar
• Justice AC. HIV and aging: Time for a new paradigm. Curr HIV/AIDS Rep. 2010;7:69–76.
   PubMedGoogle Scholar
• Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clin Infect Dis. 2008;47:542–553.
   PubMed Web of Science ®Google Scholar
• Bakanda C, Birungi J, Mwesigwa R, et al. Association of aging and survival in a large HIV-infected cohort on antiret-roviral therapy. AIDS. 201125: 701–705.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 11,2012.
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society—USA Panel. JAMA. 2012;308:387–402.
   PubMed Web of Science ®Google Scholar
• Rhee MS, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Phar-macol. 2008;48:1212–1225.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Last updated February 12,2013. Department of Health and Human Ser-vices. http://aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. (Section: HIV and the older patient, page 131)
   Google Scholar
• Curkendall SM, Richardson JT, Emons MF, et al. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2007;8:483–490.
   PubMed Web of Science ®Google Scholar
• Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29:865–874.
   PubMed Web of Science ®Google Scholar
• Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular fil-tration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–1173.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral den-sity and fractures in antiretroviral-naive persons random-ized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV Cohort Study. Clin Infect Dis. 201153: 1130–1139.
   Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons com-pared with the general population. Clin Infect Dis. 2011; 53:1120–1126.
   PubMed Web of Science ®Google Scholar
• Mothe B, Perez I, Domingo P, et al. HIV-1 infection in sub-jects older than 70: A multicenter cross-sectional assess-ment in Catalonia, Spain. Curr HIV Res. 2009;7:597–600.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–260.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230–2240.
   PubMed Web of Science ®Google Scholar
• Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 201157: 773–780.
   Google Scholar
• Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1996.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equa-tion to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Asso-ciation of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Gate J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119–1127.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compli-ance and persistence: Terminology and definitions. Value Health. 2008;11:44–47.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Cocchi D, et al. Antiretroviral treat-ment and advanced age: Epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr. 2003;33:112–114.
   PubMed Web of Science ®Google Scholar
• Grimes RM, Otiniano ME, Rodriguez-Barradas MC, et al. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis. 2002;34:1530–1533.
   PubMed Web of Science ®Google Scholar
• Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS. 200115: 1591–1593.
   Google Scholar
• Cuzin L, Delpierre C, Gerard S, et al. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis. 2007;45:654–657.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral ther-apy. Arch Intern Med. 2007;167:684–691.
   PubMed Web of Science ®Google Scholar
• Shah SS, McGowan JP, Smith C, et al. Comorbid condi-tions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis. 2002;35:1238–1243.
   PubMed Web of Science ®Google Scholar
• Gebo KA, Moore RD. Treatment of HIV infection in the older patient. Expert Rev Anti Infect Ther. 2004;2:733–743.
   PubMedGoogle Scholar
• Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329–336.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-asso-ciated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtric-itabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J Acquir Immune Defic Syndr. 2010;55:49–57
   PubMed Web of Science ®Google Scholar
• Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and fac-tors associated with renal impairment in HIV-infected patients, ANRS CO3 Aquitaine Cohort, France. HIV Med. 2010;11:308–317.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular fil-tration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353–360.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunc-tion associated with long-term use of tenofovir DF. AIDS Res Hum Retro viruses. 2009;25:387–394.
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Amadasi S, Paraninfo G, et al. The impact of gender and anchor drugs on TDF renal toxicity. J Acquir Immune Defic Syndr. 2010;55:e11–e12.
   PubMed Web of Science ®Google Scholar
• Bae JW, Guyer W, Grimm K, et al. Medication persistence in the treatment of HIV infection: A review of the literature and implications for future clinical care and research. AIDS. 201125: 279–290.
   Google Scholar
• Juday T, Grimm K, Zoe-Powers A, et al. A retrospective study of HIV antiretroviral treatment persistence in a com-mercially insured population in the United States. AIDS Care. 2011;23:1154–1162.
   PubMed Web of Science ®Google Scholar
• Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22:1951–1960.
   PubMed Web of Science ®Google Scholar
• Jarrin I, Hernández-Novoa B, Alejos B, et al. Persistence of novel first line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS; 2008-2010. Antivir Ther. 2013;18:161–170.
   PubMed Web of Science ®Google Scholar